Antibody-mediated Gene Therapy for the Treatment of Cancer
抗体介导的癌症基因疗法
基本信息
- 批准号:8119689
- 负责人:
- 金额:$ 14.27万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-09-28 至 2014-08-31
- 项目状态:已结题
- 来源:
- 关键词:5 fluorouridineAdverse effectsAffectAnimal ModelAntibodiesAntibody-Directed Enzyme Prodrug TherapyApplications GrantsAvidinAwardB lymphoid malignancyB-Cell LymphomasB-Cell NonHodgkins LymphomaB-LymphocytesBindingBystander EffectCancer PatientCell LineCellsCellular biologyChimeric ProteinsCytosineDNADevelopmentDimensionsDiseaseDrug KineticsEnvironmentEnzymesEvaluationFacultyFlucytosineFluorouracilFutureGene DeliveryGene ExpressionGenesGoalsGrowthHematopoieticHematopoietic stem cellsHodgkin DiseaseHumanIgG3ImmunoglobulinsImmunotherapyIn VitroInstitutionKnowledgeLentivirus VectorLymphomaMagicMalignant - descriptorMalignant NeoplasmsMantle Cell LymphomaMediatingMentorsMusN glycosidaseNon-Hodgkin&aposs LymphomaNormal CellOncogenesPainPharmaceutical PreparationsPlantsPositioning AttributePreparationProdrugsPropertyProtein BiosynthesisProteinsPublic HealthRattusReceptors, Antigen, B-CellReporter GenesResearchResearch PersonnelRoleSCID Beige MouseSaponariaSpecies SpecificitySprague-Dawley RatsStromal CellsSurfaceSurvival RateSystemTestingTherapeuticToxic effectToxinTrainingTransferrin ReceptorTransgenesTumor AntigensUbiquitinUnited StatesUracil phosphoribosyltransferaseXenograft procedureYeastsbasecancer cellcancer therapycareer developmentcellular pathologychimeric antibodycytotoxicityeconomic costeffective therapyexperiencegene therapyimprovedin vivonovel therapeutic interventionnovel therapeuticsoutcome forecastoverexpressionpromoterpublic health relevancereceptorreceptor mediated endocytosisselective expressionskillsstandard of caresuccesstargeted deliverytherapeutic genetransgene expressiontumorvector
项目摘要
DESCRIPTION (provided by applicant): The proposed studies focus on the development and characterization of new highly targeted gene therapy approaches for the systemic treatment of aggressive B-cell lymphomas with an emphasis on mantle cell lymphoma (MCL). Lymphomas are subdivided into Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL), of which in the United States more than 85% are NHL. MCL is an aggressive form of B-cell NHL with a very poor prognosis. MCL comprises 5-10% of NHL cases, has a median survival of about 4 years, and a long- term survival rate of less than 15%, which has not significantly changed in the past 20 years. Currently, there is no accepted standard of care for the treatment of MCL and the disease is considered incurable. Therefore, novel therapeutic approaches are urgently needed. In the strategies described in this application, MCL targeting will occur via two mechanisms: 1) through the targeting of a tumor-associated antigen (TAA) on the surface of malignant B cells and 2) through the selective expression of toxic genes using a cell-specific promoter. TAA on the surface of cancer cells serve as excellent targets for immunotherapy. Therefore, the first level of my targeted strategy will occur through the use of a mouse/human chimeric antibody-avidin fusion protein specific for the transferrin receptor (TfR). This receptor is an attractive target for cancer therapy due to its elevated expression on the surface of cancer cells, its ability to internalize, and its central role in the cellular pathology of cancer. However, the TfR is expressed on some normal cells at various levels. In order to further improve malignant cell targeting, the second level of my targeted strategy focuses on limiting the expression of toxic genes to malignant cells by using the immunoglobulin promoter. The central hypothesis of the present proposal is that TfR overexpression on the surface of MCL can be used as an effective target for TfR- mediated gene delivery, for which the transgene will be transcriptionally restricted. Since tumor targeting will occur on two levels, I also hypothesize that this strategy will be extremely effective in eliminating malignant B cells in vivo without the severe side effects that limit the efficacy of most cancer therapeutics. The antibody-avidin fusion protein that targets the TfR is a unique drug since it serves as a universal delivery system for a wide variety of biotinylated agents.
The antibody-avidin fusion protein will be conjugated to either biotinylated DNA or biotinylated lentiviral vectors in order to deliver a toxic gene into malignant B cells by receptor-mediated endocytosis. The use of two independent and non-exclusive gene therapy strategies is proposed in this application. The first gene encodes the toxin saporin, a ribosomal inactivating protein that is derived from the plant Saponaria officinialis. Saporin is a single chain toxin that cannot enter cells by itself due to the lack of a cell-binding domain. Saporin is a highly toxic and once inside the cell it inhibits protein synthesis through its N-glycosidase activity that leads to the inactivation of the 28S ribosomal subunit. The second gene that will be used encodes a chimeric yeast enzyme (FCU1) that consists of cytosine deaminse (CD) and uracil phosphoribosyltransferase (UPRT). This enzyme converts the prodrug 5-fluorocytosine to the toxic metabolites 5-fluorouracil (5-FU) and 5-fluorouridine 5'monophosphate (5-FUMP) and thus is an antibody- directed enzyme prodrug therapy (ADEPT) approach. The prodrug will be converted to its toxic metabolites within the tumor microenvironment. It is expected there will be a bystander effect associated with ADEPT therapy since the toxic metabolites can be released from targeted cells and taken up by non-targeted malignant cells in the tumor environment as well as stromal cells that support the growth of the malignant cells. Importantly, these two strategies can be used in the future in combination to maximize their anti-tumor effects. The use of this dual targeting strategy using either toxic gene is expected to increase the anti-tumor activity compared to singularly targeted agents, as well as eliminate the potential systemic toxicity of the treatment. To execute this project I propose three specific aims:
Aim 1: Reporter gene vector construction and in vitro optimization of gene delivery. Aim 2: Toxic gene vector construction and in vitro evaluation of targeted anti-cancer activity. Aim 3: Evaluation of toxicity, pharmacokinetics, and anti-tumor activity in animal models.
This project is expected to result in important advances not only in the fields of cancer gene therapy and treatment of MCL, but also in my career development. In fact, many new skills will be acquired that will increase my knowledge and research experience. This training will aid in the future preparation of grant proposals that will allow me to become a better candidate for an academic faculty position at a leading institution, which is my long-term goal. It is my goal to become an independent investigator to better understand cancer cell biology in order to develop new therapeutics that will help reduce the pain and suffering encountered by cancer patients. The outstanding research environment at UCLA, the guidance from my experienced mentors, and this award will greatly facilitate my success in reaching my goals and will open a new dimension in my professional development.
PUBLIC HEALTH RELEVANCE: Mantle Cell Lymphoma (MCL) is an aggressive and incurable form of B-cell lymphoma that has a very poor prognosis. Since there is no effective therapy for this malignancy, I propose a new combination of antibody-based and gene therapy strategies in which the antibodies will act as "magic bullets" and preferentially deliver therapeutic genes that can only be activated inside the targeted cancer cells. This strategy is expected to destroy MCL cells without affecting normal cells, eliminating the side effects of the treatment and contributing to a decrease in the human and economic cost associated with MCL.
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(1)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Tracy Ruth Daniels-Wells其他文献
Tracy Ruth Daniels-Wells的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Tracy Ruth Daniels-Wells', 18)}}的其他基金
A Novel IgE Cancer Therapeutic Specific for the Epithelial Membrane Protein-2
一种针对上皮膜蛋白 2 的新型 IgE 癌症治疗方法
- 批准号:
8727497 - 财政年份:2013
- 资助金额:
$ 14.27万 - 项目类别:
A Novel IgE Cancer Therapeutic Specific for the Epithelial Membrane Protein-2
一种针对上皮膜蛋白 2 的新型 IgE 癌症治疗方法
- 批准号:
8584977 - 财政年份:2013
- 资助金额:
$ 14.27万 - 项目类别:
Antibody-mediated Gene Therapy for the Treatment of Cancer
抗体介导的癌症基因疗法
- 批准号:
8319671 - 财政年份:2009
- 资助金额:
$ 14.27万 - 项目类别:
Antibody-mediated Gene Therapy for the Treatment of Cancer
抗体介导的癌症基因疗法
- 批准号:
8519364 - 财政年份:2009
- 资助金额:
$ 14.27万 - 项目类别:
Antibody-mediated Gene Therapy for the Treatment of Cancer
抗体介导的癌症基因疗法
- 批准号:
7941907 - 财政年份:2009
- 资助金额:
$ 14.27万 - 项目类别:
Antibody-mediated Gene Therapy for the Treatment of Cancer
抗体介导的癌症基因疗法
- 批准号:
7781438 - 财政年份:2009
- 资助金额:
$ 14.27万 - 项目类别:
相似海外基金
Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
- 批准号:
10591918 - 财政年份:2023
- 资助金额:
$ 14.27万 - 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
- 批准号:
23K15383 - 财政年份:2023
- 资助金额:
$ 14.27万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
- 批准号:
23H03556 - 财政年份:2023
- 资助金额:
$ 14.27万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
- 批准号:
23K17212 - 财政年份:2023
- 资助金额:
$ 14.27万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
- 批准号:
22H03519 - 财政年份:2022
- 资助金额:
$ 14.27万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
- 批准号:
563657-2021 - 财政年份:2022
- 资助金额:
$ 14.27万 - 项目类别:
Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10521849 - 财政年份:2022
- 资助金额:
$ 14.27万 - 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10671022 - 财政年份:2022
- 资助金额:
$ 14.27万 - 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
- 批准号:
10670918 - 财政年份:2022
- 资助金额:
$ 14.27万 - 项目类别:
Adverse Effects of Using Laser Diagnostics in High-Speed Compressible Flows
在高速可压缩流中使用激光诊断的不利影响
- 批准号:
RGPIN-2018-04753 - 财政年份:2022
- 资助金额:
$ 14.27万 - 项目类别:
Discovery Grants Program - Individual